RxDoctor Payments Data

Dorrine Goldschmidt

Optometrist · Gardendale, ALNPI 1770652380

Payments from drug & device makers

$2,280in general payments, 2019–2025

Across 61 payments — averaging $37.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$667
  • Oyster Point Pharma, Inc.$296
  • Johnson & Johnson Vision Care, Inc.$290
  • Optos, Inc.$208
  • Alcon$189
  • Coopervision Inc.$149
  • plus $481 from 10 others

What the payments were for

  • Speaking & faculty fees$502%
  • Food & beverage$2,23098%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,280 in reported general payments places this provider in the 70th percentile of 749 optometrist providers in Alabama.

See all optometrist providers in Alabama

Medicare billing

Part B allowed, 2024
$60,703
Medicare patients
277
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine75$53,049
Cyclosporine39$20,016
LumiganBimatoprost13$5,579
Loteprednol Etabonate30$4,786
Latanoprost150$2,510
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat76$1,539
Prednisolone Acetate31$1,285
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha77$1,048
Brimonidine Tartrate11$1,039
Tobramycin-DexamethasoneTobramycin/Dexamethasone15$651
MoxifloxacinMoxifloxacin Hcl17$592
Doxycycline Hyclate17$248
ErythromycinErythromycin Base18$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$62$58,62788 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$51$4,78630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 749 optometrist providers in Alabama.

Other optometrist in Gardendale

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →